Companies ›Healthcare ›BIOWKS.TE

BIOWKS.TE — — Biotechnology & Medical Research

Bio-Works Technologies AB

$3,67

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Bio-Works Technologies AB operates in the healthcare diagnostics segment, providing diagnostic solutions and related services to healthcare providers and research institutions.

Business. Bio-Works Technologies AB (BIOWKS.TE) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is headquartered in Sweden. Specific details regarding operating segments and geographic revenue mix are not available. The company is listed under the ticker BIOWKS.TE.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning BIOWKS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to BIOWKS.TE. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Bio-Works Technologies AB (BIOWKS.TE) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm generates revenue through product sales and is headquartered in Sweden. Specific details regarding operating segments and geographic revenue mix are not available. The company is listed under the ticker BIOWKS.TE.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

Bio-Works Technologies AB has an equal number of basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

Profitability and return metrics are not available for comparison against industry benchmarks, as no financial performance data is provided in the valuation snapshot.

The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess segment or regional risk.

Growth trajectory is not quantified in the outlook, and no numeric deltas are provided for the current or next fiscal year.

Risk factors include the inability to assess liquidity risk, which may affect the company's ability to meet short-term obligations. No dilution sources are identified, and no adjustments have been applied to valuation metrics.

Recent events, such as filings or transcripts, are not disclosed in the available data.

Key takeaways

Bio-Works Technologies AB operates in the healthcare diagnostics industry, serving healthcare providers and research institutions.
The company has no dilution risk based on current share structure.
Liquidity risk could not be assessed due to missing balance-sheet data.
No profitability or return metrics are available for comparison with industry benchmarks.
Growth and risk outlooks are not quantified in the available data.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Annual

ANNUALFiled 2024-02-19

FY 2024 · Full-year highlights

Revenue kr 43.9M, +6,2% YoY; Operating income −22,2% YoY.

Revenuekr 43.9M+6,2 % YoY

Operating income-kr 56.3M−22,2 % YoY

Net income-kr 56.8M−26,4 % YoY

Free cash flow-kr 57.1M−25,2 % YoY

EPS—

Operating cash flow-kr 59.0M−47,9 % YoY

Financials

Income statement

Revenuekr 43.9M

Gross profitkr 26.8M

Operating income-kr 56.3M

Net income-kr 56.8M

Margins

Gross margin61.1%

Operating margin-128.4%

Net margin-129.4%

FCF margin-130.0%

Balance sheet

Total assetskr 62.2M

Total liabilitieskr 18.1M

Total equitykr 44.0M

Cash & equivalents—

Long-term debtkr 0.00

Cash flow

Operating cash flow-kr 59.0M

CapEx-kr 860.0k

Free cash flow-kr 57.1M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue kr 43.9M, +6,2% YoY
▍Operating income −22,2% YoY
▍Net income −26,4% YoY
▍Free cash flow −25,2% YoY
▍Net margin -129.4%

Valuation FY

Market price

$3,67

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic

Source documents

Bio-Works Technologies AB Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

BIOWKS.TECanonical

— · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2024-02-19 08:45 UTCEARNINGSAnnual results — FY 2024 Revenue SEK 43.9M · Net SEK -56.8M

2023-02-17 14:46 UTCEARNINGSAnnual results — FY 2023 Revenue SEK 41.3M · Net SEK -45.0M

2022-02-18 09:09 UTCEARNINGSAnnual results — FY 2022 Revenue SEK 21.9M · Net SEK -12.9M

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread